Biogen Idec, Abbott Enroll First Patient In Daclizumab Phase III Study
Daclizumab is a humanised monoclonal antibody that binds to CD25, a receptor subunit that is expressed at low levels on resting T-cells and at high levels on T-cells
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Kevetrin is being developed to treat drug resistant cancers. Cellceutix claimed that Kevetrin showed greater tumor growth delay than standard therapies in animal models of resistant lung cancer,